SCHEMBL2132702

SCHEMBL2132702

Clc1ccc(/C=C/c2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 1.00
ALOX5 P09917 1/20 0.57
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
DAO P14920 1/20 0.50
CYP1A2 P05177 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
NFE2L2 Q16236 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143573 1.00 AHR (1.00) AHRALOX5PTGS1PTGS2DAO
SCHEMBL6460048 1.00 AHR (1.00) AHRALOX5PTGS1PTGS2DAO
SCHEMBL260347 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL1795502 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL9679429 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL699666 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL9679426 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL10458457 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL20582895 0.86 AHR (0.74) AHRALOX5PTGS1PTGS2DAO
SCHEMBL18002529 0.84 AHR (0.72) AHRALOX5PTGS1PTGS2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224460-A1 METHODS FOR INDUCING NATURAL KILLER CELL DIFFERENTIATION PLASTICELL LTD (GB) 2025-10-30 WO claimed
WO-2025201290-A1 METHOD FOR PREPARING PLATELETS 苏州血霁生物科技有限公司 2025-10-02 WO claimed
CN-120033996-A Low-cost high-voltage charge pump voltage stabilizing circuit and control method thereof 上海帝迪集成电路设计有限公司 2025-05-23 CN claimed
WO-2025073655-A2 USE OF ARTIFICIAL MARROW ORGANOID FOR GENERATING NK CELLS AND MYELOID CELLS Institut National de la Santé et de la Recherche Médicale (FR) 2025-04-10 WO claimed
CN-119739238-A Voltage stabilizing starting circuit without operational amplifier and applied to high voltage and voltage stabilizing starting method thereof 上海帝迪集成电路设计有限公司 2025-04-01 CN claimed
WO-2025051967-A1 METHOD OF PRODUCING PLASMACYTOID DENDRITIC CELLS UNIKUM THERAPEUTICS APS (DK) 2025-03-13 WO claimed
EP-4444870-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2024-10-16 EP claimed
CN-118382694-A Methods and compositions for generating human erythroid progenitors 特雷尔赫德生物系统股份有限公司 2024-07-23 CN claimed
CN-117850204-A Process image sharing across multiple programmable automation controllers 施耐德电气工业公司 2024-04-09 CN claimed
EP-4345559-A1 PROCESS IMAGE SHARING ACROSS MULTIPLE PROGRAMMABLE AUTOMATION CONTROLLERS Schneider Electric Industries SAS (FR) 2024-04-03 EP claimed
CN-114349822-B Biological macromolecule modification method based on vinyl sulfonium salt 深圳湾实验室坪山生物医药研发转化中心 2023-10-20 CN claimed
WO-2023107477-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2023-06-15 WO claimed
US-20230174938-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. 2023-06-08 US claimed
US-20230032216-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) 2023-02-02 US claimed
EP-4073273-A1 INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2022-10-19 EP claimed
CN-114349822-A Biomacromolecule modification method based on vinyl sulfonium salt 深圳湾实验室坪山生物医药研发转化中心 2022-04-15 CN claimed
US-20260145318-A1 Method for Operating a Device Networking System LUCOMM TECHNOLOGIES, INC. (US) 2026-05-28 US disclosed
US-20260147346-A1 Method for Operating a Semantic System LUCOMM TECHNOLOGIES, INC. (US) 2026-05-28 US disclosed
WO-2004041758-A1 NEW STILBENE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR LIGAND ANTAGONISTICS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) 2004-05-21 WO disclosed
EP-1418164-A1 New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2004-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260145318-A1 Method for Operating a Device Networking System IL33, TRIM33, MICOS13 AHR 1328/4885ALOX5 3877/4885PTGS1 1323/4885
US-20260147346-A1 Method for Operating a Semantic System RAP1A, RIF1, TRRAP AHR 3790/4885ALOX5 3427/4885PTGS1 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.